<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02621541</url>
  </required_header>
  <id_info>
    <org_study_id>P-NETPET</org_study_id>
    <nct_id>NCT02621541</nct_id>
  </id_info>
  <brief_title>Nonfunctional Pancreatic NET and PET Imaging</brief_title>
  <official_title>Dual Tracer Functional Imaging of Nonfunctional Pancreatic Neuroendocrine Tumors Using 68Ga-DOTA-NOC and 18F-FDG PET/CT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Predicting aggressive behavior in the group of nonfunctional pancreatic neuroendocrine tumors
      (NF P-NET) remains a difficult problem in clinical practice. At present, the treatment
      planning in P-NET is significantly restricted by the limited results of conventional imaging.
      In addition, increasing use of multidetector computed tomography (MDCT) and magnetic
      resonance imaging (MRI) is increasing the number of NF P-NETs detected. Somatostatin receptor
      scintigraphy (SRS) combined with anatomical imaging are the conventional modalities in
      imaging of P-NET, but by these methods the diagnostic accuracy still remains compromised.
      Furthermore, recently encouraging results have been obtained in P-NET using 68Ga-labelled
      somatostatin analog, DOTA-1-NaI3-octreotide (68Ga-DOTANOC) positron emission
      tomography-computed tomography (PET-CT).

      The aim of the current project is to evaluate the possibility to enhance the diagnostic
      accuracy by using dual trace functional imaging 18F-labelled fluorodeoxyglucose (18F-FDG) and
      68Ga-DOTANOC PET-CT imaging in patients with NF P-NET. The study consists of 20 patients with
      NF P-NET. The patients enrolled in the study will be imaged 68Ga-DOTANOC and 18F-FDG PET-CT
      followed by surgery or follow-up with endoscopic ultrasonography (EUS) biopsies. The data
      will be collected between autumn 2015 and spring 2018.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The SUV of 68Ga-DOTANOC and 18F-FDG PET-CT predict the malignant potential of P-NETs</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Diagnosis</condition>
  <arm_group>
    <arm_group_label>Preoperative diagnosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preoperative diagnosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PET/CT</intervention_name>
    <arm_group_label>Preoperative diagnosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  suspicion of nonfunctional P-NET on primary CT (i.e hypervascularity) or MRI

          -  signed informed consent

        Exclusion Criteria:

          -  vulnerable study subjects such as described in Finnish law concerning clinical studies
             (disabled, children, pregnant or breast-feeding women, prisoners) will not be
             included.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saila Kauhanen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turku University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Saila Kauhanen</last_name>
    <phone>+358503017010</phone>
    <email>saila.kauhanen@utu.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>HUS Vatsakeskus</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanna Sepp√§nen, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Turku Division of Digestive Surgery and Urology</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saila Kauhanen, MD, PhD</last_name>
      <phone>+358 503017010</phone>
    </contact>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2015</study_first_submitted>
  <study_first_submitted_qc>December 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2015</study_first_posted>
  <last_update_submitted>January 5, 2016</last_update_submitted>
  <last_update_submitted_qc>January 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neuroendocrine tumor</keyword>
  <keyword>pancreas</keyword>
  <keyword>diagnosis</keyword>
  <keyword>positron emission tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

